Advancing Oligonucleotide Therapeutics

COMPANY Soluventis Nanotherapeutics is developing a new class of oligonucleotide therapeutics based on its proprietary platform technology.	THERAPEUTICS Proprietary drug candidates for oncology are in preclinical studies. The company puts particular emphasis on developing a new therapeutic concept for the pediatric bone cancer Ewing's sarcoma.	PLATFORM TECHNOLOGY An entirely new type of Nano- carrier, characterized by high efficacy and a very good safety profile having the capability to transport therapeutic oligonucleotides and peptides.	SERVICES Besides the internal research & development programs, Soluventis offers collaboration projects.
LEARN MORE	LEARN MORE	LEARN MORE	LEARN MORE